. home.aspx

NEWS

home.aspx
   


Adaptive Phage gets $10M from DoD for antibacterial phage therapies

January 08, 2020 / MedCity News
SHARESHARESHARE

A company developing treatments for drug-resistant bacterial infections is getting a boost from the Department of Defense. Gaithersburg, Maryland-based Adaptive Phage Therapeutics, also known as APT, said Tuesday that it the DoD had awarded it $10.2 million to fund a clinical trial to develop its personalized bacteriophage therapeutic, PhageBank. “This is a promising step toward making phage therapy available to military and potentially non-military patients alike as a rapid and cost-effective option for multi-drug resistant bacterial infections,” APT CEO Greg Merril said in a statement. “APT’s proprietary technologies enable the rapid administration of phage therapy as a precise treatment tailored to a patient’s individual infection.”